The Food and Drug Administration fully approved the Alzheimer’s drug Leqembi, meant to slow development of the disease. Treatment costs $26,500 per year and is only approved for people in the early stages of Alzheimer's.
FDA grants first ever approval for Alzheimer’s drug meant to slow disease
